HRP20240765T1 - Pangenotipska sredstva protiv virusa influence i postupci njihove primjene - Google Patents

Pangenotipska sredstva protiv virusa influence i postupci njihove primjene Download PDF

Info

Publication number
HRP20240765T1
HRP20240765T1 HRP20240765TT HRP20240765T HRP20240765T1 HR P20240765 T1 HRP20240765 T1 HR P20240765T1 HR P20240765T T HRP20240765T T HR P20240765TT HR P20240765 T HRP20240765 T HR P20240765T HR P20240765 T1 HRP20240765 T1 HR P20240765T1
Authority
HR
Croatia
Prior art keywords
oligonucleotide
compound
lna
seq
virus
Prior art date
Application number
HRP20240765TT
Other languages
English (en)
Croatian (hr)
Inventor
Jeffrey S. Glenn
Rachel HAGEY
Edward Pham
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of HRP20240765T1 publication Critical patent/HRP20240765T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HRP20240765TT 2016-03-02 2017-03-01 Pangenotipska sredstva protiv virusa influence i postupci njihove primjene HRP20240765T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302548P 2016-03-02 2016-03-02
EP20208373.9A EP3800257B1 (en) 2016-03-02 2017-03-01 Pan-genotypic agents against influenza virus and methods of using the same

Publications (1)

Publication Number Publication Date
HRP20240765T1 true HRP20240765T1 (hr) 2024-09-13

Family

ID=59743201

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240765TT HRP20240765T1 (hr) 2016-03-02 2017-03-01 Pangenotipska sredstva protiv virusa influence i postupci njihove primjene

Country Status (17)

Country Link
US (1) US10597658B2 (cg-RX-API-DMAC7.html)
EP (3) EP4389221A3 (cg-RX-API-DMAC7.html)
JP (3) JP7536272B2 (cg-RX-API-DMAC7.html)
CN (1) CN108778344A (cg-RX-API-DMAC7.html)
CA (1) CA3014776A1 (cg-RX-API-DMAC7.html)
DK (1) DK3800257T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981765T3 (cg-RX-API-DMAC7.html)
FI (1) FI3800257T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240765T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066977T2 (cg-RX-API-DMAC7.html)
LT (1) LT3800257T (cg-RX-API-DMAC7.html)
PL (1) PL3800257T3 (cg-RX-API-DMAC7.html)
PT (1) PT3800257T (cg-RX-API-DMAC7.html)
RS (1) RS65707B1 (cg-RX-API-DMAC7.html)
SI (1) SI3800257T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400253T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017151795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
CN115997014A (zh) * 2020-02-14 2023-04-21 小利兰·斯坦福大学董事会 抗呼吸道病毒的泛基因型药剂及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501843A (ja) * 1990-08-14 1994-03-03 アイシス・ファーマシューティカルス・インコーポレーテッド アンチセンスオリゴヌクレオチドによるインフルエンザa型ウイルス,アン・アーバh2n2株の阻害
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
CA2603842A1 (en) * 2005-04-08 2006-10-19 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
EP2239328A3 (en) * 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
WO2007084359A2 (en) * 2006-01-17 2007-07-26 Oligos Etc., Inc. Compositions and methods for the treatment of influenza infection
AU2007310982A1 (en) * 2006-10-18 2008-04-24 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20090042823A1 (en) 2007-08-10 2009-02-12 Mdrna, Inc. Uses of broad spectrum rnai therapeutics against influenza
US20120003156A1 (en) 2008-07-01 2012-01-05 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
SI2607484T1 (sl) 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
AU2010319314C1 (en) * 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现

Also Published As

Publication number Publication date
EP3423107A1 (en) 2019-01-09
WO2017151795A1 (en) 2017-09-08
JP2019511471A (ja) 2019-04-25
HUE066977T2 (hu) 2024-09-28
PL3800257T3 (pl) 2024-09-16
SI3800257T1 (sl) 2025-04-30
US20190136242A1 (en) 2019-05-09
DK3800257T3 (da) 2024-06-24
JP2025096365A (ja) 2025-06-26
JP7536272B2 (ja) 2024-08-20
LT3800257T (lt) 2024-07-25
ES2981765T3 (es) 2024-10-10
CN108778344A (zh) 2018-11-09
CA3014776A1 (en) 2017-09-08
RS65707B1 (sr) 2024-08-30
EP3800257B1 (en) 2024-05-01
US10597658B2 (en) 2020-03-24
PT3800257T (pt) 2024-06-26
SMT202400253T1 (it) 2024-09-16
EP4389221A2 (en) 2024-06-26
EP4389221A3 (en) 2024-11-20
FI3800257T3 (fi) 2024-06-19
EP3423107A4 (en) 2020-01-15
EP3800257A1 (en) 2021-04-07
JP2022176378A (ja) 2022-11-25

Similar Documents

Publication Publication Date Title
Byrn et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit
Workenhe et al. Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes
HRP20210315T1 (hr) Oligonukleotidi za smanjenje ekspresije pd-l1
Figlerowicz et al. Genetic variability: The key problem in the prevention and therapy of RNA‐based virus infections
Bray et al. Experimental therapy of filovirus infections
HRP20201125T1 (hr) Antisens nukleinska kiselina
PE20220574A1 (es) Oligonucleotidos gapmer modificados y metodos de uso
Suenaga et al. An aptamer that binds efficiently to the hemagglutinins of highly pathogenic avian influenza viruses (H5N1 and H7N7) and inhibits hemagglutinin–glycan interactions
HRP20241138T1 (hr) Oligonukleotidi za induciranje ekspresije očinskog ube3a
HRP20192177T1 (hr) Rnai pripravci za virus hepatitisa b (hbv) i postupci njihove upotrebe
Aguilar et al. Emerging paramyxoviruses: molecular mechanisms and antiviral strategies
MX2024005653A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
HRP20160336T1 (hr) Protusmjerna nukleinska kiselina
FI3800257T3 (fi) Pan-genotyyppisiä aineita influenssavirusta vastaan ja menetelmiä niiden käyttämiseksi
Gonzalez Aparicio et al. A virus is a community: diversity within negative-sense RNA virus populations
WO2006121464A3 (en) Compositions for treating respiratory viral infections and their use
US20140287023A1 (en) 5'-triphosphate oligoribonucleotides
Uematsu et al. Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S-(4-nitrobenzyl)-6-thioinosine
Stincarelli et al. Reassortment ability of the 2009 pandemic H1N1 influenza virus with circulating human and avian influenza viruses: public health risk implications
JP2019511471A5 (cg-RX-API-DMAC7.html)
Barnard Inhibitors of measles virus
Gaajetaan et al. The type I interferon response during viral infections: a “SWOT” analysis
HRP20211525T1 (hr) Molekule sirna specifične za notch 1
TWI670064B (zh) 抗病毒劑及治療病毒感染之方法
JP2023514576A5 (cg-RX-API-DMAC7.html)